Skip to content

Study · Measured the body's own peptide · 2013

6 results

Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.

Jou YC, Tsai YS, Hsieh HY, Chen SY, Tsai HT, Chen KJ, Wang ST, Shiau AL, Wu CL, Tzai TS

Urologic oncology19 May 2012Cited by 7 (Europe PMC)

PMID22609059 (opens in a new tab)DOI10.1016/j.urolonc.2012.03.011 (opens in a new tab)PepBankPUB-22609059
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Natural levels measured6

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with renal cell carcinoma, plasma thymosin-α1 levels were lower than in patients with urothelial carcinoma or benign urologic disease.

    In plain wordsPatients with renal cell carcinoma had lower levels of the body's own thymosin-α1 in blood than patients with urothelial carcinoma or benign disease.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreasePlasma thymosin-α1 in RCC versus UC and benign disease
    Study

    n: not reported in source

    Comparator
    Urothelial carcinoma and benign urologic disease
    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    Plasma TA1 levels were significantly lower in RCC patients than in UC or benign patients, particularly in UC of the renal pelvis patients (P < 0.0001).
    2 context sentences
    Summary · context
    Blood samples were taken from 50 consecutive patients with RCC, 97 with UC, and 55 with benign urologic diseases before surgery.
    Summary · context
    Plasma TA1 and PTMA levels were measured using enzyme-linked immunosorbent assay and their correlation with tumor grade, pathologic stage, and survival were explored.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In patients with bladder cancer, plasma thymosin-α1 levels correlated inversely with pathologic stage.

    In plain wordsIn bladder cancer patients, higher disease stage was linked to lower levels of the body's own thymosin-α1.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreasePlasma thymosin-α1 correlation with pathologic stage in bladder cancer
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    Plasma TA1 levels inversely correlated with pathologic stage both in bladder cancer and RCC patients (P = 0.03 and 0.02, respectively).
    2 context sentences
    Summary · context
    Blood samples were taken from 50 consecutive patients with RCC, 97 with UC, and 55 with benign urologic diseases before surgery.
    Summary · context
    Plasma TA1 and PTMA levels were measured using enzyme-linked immunosorbent assay and their correlation with tumor grade, pathologic stage, and survival were explored.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In patients with renal cell carcinoma, plasma thymosin-α1 levels correlated inversely with pathologic stage.

    In plain wordsIn renal cell carcinoma patients, higher disease stage was linked to lower levels of the body's own thymosin-α1.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreasePlasma thymosin-α1 correlation with pathologic stage in renal cell carcinoma
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    Plasma TA1 levels inversely correlated with pathologic stage both in bladder cancer and RCC patients (P = 0.03 and 0.02, respectively).
    2 context sentences
    Summary · context
    Blood samples were taken from 50 consecutive patients with RCC, 97 with UC, and 55 with benign urologic diseases before surgery.
    Summary · context
    Plasma TA1 and PTMA levels were measured using enzyme-linked immunosorbent assay and their correlation with tumor grade, pathologic stage, and survival were explored.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    In patients with renal cell or urothelial carcinoma, plasma thymosin-α1 levels did not correlate with tumor grade.

    In plain wordsIn patients with kidney or urinary tract cancer, levels of the body's own thymosin-α1 were not linked to tumor grade.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changePlasma thymosin-α1 correlation with tumor grade
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    Both plasma TA1 and PTMA did not correlate with tumor grade.
    2 context sentences
    Summary · context
    Blood samples were taken from 50 consecutive patients with RCC, 97 with UC, and 55 with benign urologic diseases before surgery.
    Summary · context
    Plasma TA1 and PTMA levels were measured using enzyme-linked immunosorbent assay and their correlation with tumor grade, pathologic stage, and survival were explored.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  5. 05HumanEndogenous levelObservational studyOther

    In patients with bladder cancer, plasma thymosin-α1 was a prognostic indicator for progression-free survival.

    In plain wordsIn bladder cancer patients, the body's own thymosin-α1 level in blood was linked to how long disease stayed controlled.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicablePlasma thymosin-α1 as prognostic indicator of progression-free survival
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    Plasma TA1 was a prognostic indicator for progression-free and disease-specific overall survival in bladder cancer patients (P = 0.008 and 0.04, respectively).
    2 context sentences
    Summary · context
    Blood samples were taken from 50 consecutive patients with RCC, 97 with UC, and 55 with benign urologic diseases before surgery.
    Summary · context
    Plasma TA1 and PTMA levels were measured using enzyme-linked immunosorbent assay and their correlation with tumor grade, pathologic stage, and survival were explored.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  6. 06HumanEndogenous levelObservational studyOther

    In patients with bladder cancer, plasma thymosin-α1 was a prognostic indicator for disease-specific overall survival.

    In plain wordsIn bladder cancer patients, the body's own thymosin-α1 level in blood was linked to survival from the disease.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicablePlasma thymosin-α1 as prognostic indicator of disease-specific overall survival
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    Plasma TA1 was a prognostic indicator for progression-free and disease-specific overall survival in bladder cancer patients (P = 0.008 and 0.04, respectively).
    2 context sentences
    Summary · context
    Blood samples were taken from 50 consecutive patients with RCC, 97 with UC, and 55 with benign urologic diseases before surgery.
    Summary · context
    Plasma TA1 and PTMA levels were measured using enzyme-linked immunosorbent assay and their correlation with tumor grade, pathologic stage, and survival were explored.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.